0001437749-22-010726.txt : 20220503
0001437749-22-010726.hdr.sgml : 20220503
20220503191216
ACCESSION NUMBER: 0001437749-22-010726
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220410
FILED AS OF DATE: 20220503
DATE AS OF CHANGE: 20220503
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Scott John K Jr.
CENTRAL INDEX KEY: 0001753763
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35076
FILM NUMBER: 22889087
MAIL ADDRESS:
STREET 1: 30 BLUE HERON DR.
CITY: GREENWOOD VILLAGE
STATE: CO
ZIP: 80121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NAVIDEA BIOPHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000810509
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 311080091
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4995 BRADENTON AVENUE
STREET 2: SUITE 240
CITY: DUBLIN
STATE: OH
ZIP: 43017
BUSINESS PHONE: 6147937500
MAIL ADDRESS:
STREET 1: 4995 BRADENTON AVENUE
STREET 2: SUITE 240
CITY: DUBLIN
STATE: OH
ZIP: 43017
FORMER COMPANY:
FORMER CONFORMED NAME: NEOPROBE CORP
DATE OF NAME CHANGE: 19940714
4
1
rdgdoc.xml
FORM 4
X0306
4
2022-04-10
0000810509
NAVIDEA BIOPHARMACEUTICALS, INC.
NAVB
0001753763
Scott John K Jr.
4995 BRADENTON AVE., SUITE 240
DUBLIN
OH
43017
1
1
Common Stock
2022-04-30
4
A
0
2500
0
A
8093395
D
Common Stock
10139
I
By spouse and children
Series G Redeemable Preferred Stock
2022-04-10
4
P
0
3260
A
3260
D
Series E Redeemable Convertible Preferred Stock
2.30
2022-04-10
4
S
0
50000
2.30
D
2021-03-02
2022-09-02
Common Stock
2173913
0
D
Series F Redeemable Convertible Preferred Stock
0.80
2022-04-10
4
P
0
1740
0.80
A
2022-04-10
Common Stock
2175000
1740
D
Stock issued under the Amended and Restated 2014 Stock Incentive Plan in partial payment of monthly non-employee director fees.
Issuance deferred at the request of the Reporting Person.
Includes 2,639 shares of Common Stock owned by the Reporting Person's spouse and 7,500 shares of Common Stock owned by the Reporting Person's children. The Reporting Person may be deemed to have shared voting and/or dispositive power with respect to such shares.
Series E Redeemable Convertible Preferred Stock, par value $.001 per share, was exchanged for Series F Redeemable Convertible Preferred Stock, par value $.001 per share, and Series G Redeemable Preferred Stock, par value $.001 per share.
Series F Redeemable Convertible Preferred Stock, par value $.001 per share, is convertible at any time and has no expiration date.
/s/ Erika L. Eves for John K. Scott, Jr. by power of attorney
2022-05-03